Fatty Liver Index As an Independent Predictor of All-cause and Disease-specific Mortality

Overview

Journal Eur J Gastroenterol Hepatol

Specialty Gastroenterology

Date 2024 Oct 14

PMID 39400538

Authors

Ruixin Zhang

Shuhao Ren

Hongfei Mi

Meixia Wang

Tingjuan He

Renyan Zhang

Wei Jiang

Chenghao Su

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aims to assess the prognostic value of the fatty liver index (FLI), a noninvasive tool for hepatic steatosis assessment, in predicting all-cause and disease-specific mortality.

Methods: We linked data from the National Health and Nutrition Examination Survey III (1988-1994) with Public-Use Mortality Files, forming a cohort of 11 297 participants with a median follow-up period of 26.25 years. Cox proportional hazards models were used to evaluate the association between FLI and all-cause mortality, while Fine and Gray's models assessed the relationship between FLI and disease-specific mortality.

Results: The FLI ≥ 60 was independently associated with an increased risk of all-cause mortality (hazard ratio = 1.24, P < 0.001), as well as mortality from malignant neoplasms (hazard ratio = 1.18, P = 0.048), diabetes (hazard ratio = 2.62, P = 0.001), and cardiovascular diseases (CVDs) (hazard ratio = 1.18, P = 0.018), compared to FLI < 30. No significant associations were found with Alzheimer's disease, influenza and pneumonia, chronic lower respiratory diseases, or renal disorders. Subgroup analyses indicated that individuals who were females aged 40-60 (hazard ratio = 1.67, P = 0.003), non-overweight (hazard ratio = 1.75, P = 0.007), or without abdominal obesity (hazard ratio = 1.75, P = 0.007) exhibited a stronger association between FLI ≥ 60 and all-cause mortality.

Conclusion: These findings support the prognostic value of the FLI for predicting mortality from all causes, malignant neoplasms, diabetes, and CVDs. Targeted attention is needed in postmenopausal women, non-overweight, and non-abdominally obese populations.

References

Boeckmans J, Sandrin L, Knackstedt C, Schattenberg J . Liver stiffness as a cornerstone in heart disease risk assessment. Liver Int. 2023; 44(2):344-356. DOI: 10.1111/liv.15801. View

Wongtrakul W, Charatcharoenwitthaya N, Charatcharoenwitthaya P . Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2024; 36(4):351-358. DOI: 10.1097/MEG.0000000000002719. View

Lee J, Kim D, Kim H, Lee C, Yang J, Kim W . Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2009; 42(7):503-8. DOI: 10.1016/j.dld.2009.08.002. View

Ma W, Wu W, Wen W, Xu F, Han D, Lyu J . Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. Ther Adv Chronic Dis. 2022; 13:20406223221122478. PMC: 9493675. DOI: 10.1177/20406223221122478. View

Rinella M, Neuschwander-Tetri B, Siddiqui M, Abdelmalek M, Caldwell S, Barb D . AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77(5):1797-1835. PMC: 10735173. DOI: 10.1097/HEP.0000000000000323. View

Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

Golabi P, Paik J, Reddy R, Bugianesi E, Trimble G, Younossi Z . Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol. 2019; 19(1):56. PMC: 6469055. DOI: 10.1186/s12876-019-0972-6. View

Huang H, Liu Z, Xie J, Xu C . NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis. J Psychiatr Res. 2023; 161:435-440. DOI: 10.1016/j.jpsychires.2023.03.041. View

Xu H, Yan R, Ye C, Li J, Ji G . Specific mortality in patients with diffuse large B-cell lymphoma: a retrospective analysis based on the surveillance, epidemiology, and end results database. Eur J Med Res. 2024; 29(1):241. PMC: 11031870. DOI: 10.1186/s40001-024-01833-4. View

10.

Unalp-Arida A, Ruhl C . Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology. 2015; 63(4):1170-83. PMC: 4805455. DOI: 10.1002/hep.28390. View

11.

McKenzie J, Fisher B, Jaap A, Stanley A, Paterson K, Sattar N . Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2006; 65(1):40-4. DOI: 10.1111/j.1365-2265.2006.02543.x. View

12.

Park J, Hong J, Han K, Kang W, Park J . Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. Sci Rep. 2022; 12(1):10681. PMC: 9226051. DOI: 10.1038/s41598-022-14856-w. View

13.

Feldman A, Eder S, Felder T, Kedenko L, Paulweber B, Stadlmayr A . Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol. 2016; 112(1):102-110. DOI: 10.1038/ajg.2016.318. View

14.

Smith Jr S, Benjamin E, Bonow R, Braun L, Creager M, Franklin B . AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124(22):2458-73. DOI: 10.1161/CIR.0b013e318235eb4d. View

15.

Riazi K, Azhari H, Charette J, Underwood F, King J, Afshar E . The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851-861. DOI: 10.1016/S2468-1253(22)00165-0. View

16.

Chen J, Mao X, Deng M, Luo G . Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD. Eur J Gastroenterol Hepatol. 2023; 35(4):394-401. PMC: 9951794. DOI: 10.1097/MEG.0000000000002497. View

17.

Moon J, Jeong S, Jang H, Koo B, Kim W . Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023; 65:102292. PMC: 10632413. DOI: 10.1016/j.eclinm.2023.102292. View

18.

Nong Y, Wu G, Lu J, Wei X, Yu D . The mediating role of obesity in the development of depression in individuals with diabetes: A population-based study from NHANES 2005-2014. J Affect Disord. 2024; 351:977-982. DOI: 10.1016/j.jad.2024.02.036. View

19.

Crudele L, De Matteis C, Novielli F, Di Buduo E, Petruzzelli S, De Giorgi A . Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men. Biol Sex Differ. 2024; 15(1):43. PMC: 11100212. DOI: 10.1186/s13293-024-00617-z. View

20.

Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T . Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep. 2014; 2(5):633-636. PMC: 4106613. DOI: 10.3892/br.2014.309. View